Inhibition of angiogenesis in the treatment of non-small cell lung cancer (Q36950548)

17 August 2017

1 reference

title

Inhibition of angiogenesis in the treatment of non-small cell lung cancer (English)

1 reference

17 August 2017

1 reference

Vicki L Keedy

1 reference

17 August 2017

Alan B Sandler

series ordinal

1 reference

17 August 2017

publication date

24 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1825-1830

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Role of vascular endothelial growth factor in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00620.X

10.1111/J.1349-7006.2007.00620.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference